Alliances that move a programme forward.
We structure co-development, manufacturing, and joint commercialization partnerships that let two organizations build value neither could capture alone – matched on science, geography, and intent before a single term is drafted.
From a shared thesis to a working alliance.
We do the quiet work that decides whether a partnership holds: aligning incentives, pressure-testing the science, and writing economics that survive a change of plan. Each mandate is shaped around the deal in front of us, not a template.
Partner identification
We map the realistic universe of counterparties for a given asset or capability and qualify intent before introductions are ever made.
- Strategic fit screening
- Counterparty shortlist
- Confidential outreach
Deal architecture
We design the shape of the alliance – scope, governance, and the split of cost, risk, and reward – so the structure reflects how value is actually created.
- Economic modelling
- Governance design
- Risk allocation
Negotiation & close
We sit at the table through term sheet, diligence, and definitive agreements, holding the deal together across legal, scientific, and commercial workstreams.
- Term-sheet leadership
- Diligence management
- Signing to close
Partnerships are won in the detail.
Most alliances fail not at signing but in the months after, when ambiguity surfaces. We engineer for that future from the first conversation.
Aligned incentives
We build economics where both sides win in the same direction. When interests diverge later, the structure already anticipated it.
Cross-border fluency
Co-development and manufacturing across Africa, the Gulf, Europe, and the United States carry regulatory and cultural seams. We work them every day.
Senior at the table
The partner who scopes your mandate is the one who negotiates it. No handoff to a junior bench once the work gets hard.
Built to last
We optimize for the alliance that still works in year three – clear governance, honest milestones, and exits that nobody has to litigate.
A four-step path to a signed alliance.
Disciplined enough to protect both parties, flexible enough to fit the deal.
Frame
We define the objective, the assets in play, and what a good outcome looks like for the partnership – before any name is shared.
Match
We surface qualified counterparties, test mutual appetite quietly, and bring only credible parties into the room.
Structure
We model the economics, draft the term sheet, and run scientific, legal, and commercial diligence in parallel.
Close
We drive definitive agreements to signature and set the governance that carries the alliance into execution.
Six lenses on every alliance.
We test a partnership the way it will be tested in practice – across science, operations, and the people on both sides.
Scientific fit
Whether the combined programmes, platforms, or pipelines genuinely reinforce each other.
Commercial logic
The market, the access path, and who is best placed to commercialize where.
Operational capacity
Manufacturing, supply, and the ability of each side to deliver on its side of the deal.
Regulatory path
Filing strategy and approval timelines across each market the alliance will touch.
Economic balance
Cost, milestone, royalty, and equity terms tested against a range of futures.
Cultural alignment
Whether the two organizations can actually decide and execute together over years.
One team across the corridor.
Partnerships rarely sit in a single market. Our desks coordinate so the deal feels local on both sides of the border.
Africa & emerging markets
Manufacturing capacity, regional registration, and access partnerships across high-growth markets.
Gulf desk
Sovereign capital, distribution alliances, and the bridge between East and West.
Europe & Americas
Co-development with originators, global commercialization, and access to deep biotech ecosystems.
Shapes a partnership can take.
We start from the value being created, then choose the structure – never the reverse.
| Co-development | Shared cost and risk across a programme, with defined decision rights and milestone-linked economics. |
|---|---|
| Manufacturing & supply | Contract or strategic supply across markets, including tech transfer and capacity commitments. |
| Joint commercialization | Co-promotion or territory-split launch, aligning each partner to where it sells best. |
| Platform collaboration | Access to a technology or discovery platform under option, royalty, or equity terms. |
| Strategic equity | Investment paired with collaboration, aligning balance-sheet and pipeline interests. |
Where our network runs deepest.
Partnership relationships across the modalities and areas that define the pipeline.
Oncology
ADCs, bispecifics, and targeted small molecules.
Immunology
Autoimmune, inflammation, and immunomodulators.
Metabolic
GLP-1 combinations, NASH, and cardiometabolic.
Cell & Gene
CAR-T, allogeneic, and gene therapy.
CNS
Neurodegeneration, psychiatry, and rare neuro.
Rare Disease
Orphan and ultra-rare programmes.
Devices & Dx
Devices, diagnostics, and companion Dx.
Digital Health
AI-led discovery, trial tech, and DTx.
Anonymized, by outcome.
Every engagement is confidential. These are the shapes of work we are trusted to lead.
Oncology platform alliance
Paired a Gulf-backed developer with a European biotech on an ADC programme, splitting development cost and structuring milestone economics to term sheet in under five months.
Regional supply partnership
Structured a tech-transfer and supply agreement bringing a US originator’s metabolic product into African manufacturing, with phased capacity commitments.
Cross-border launch
Aligned two partners on a territory-split commercialization of a rare-disease asset, matching each to the markets where it could move fastest.